Pay in 4 interest-free payments of $22.50 Learn more
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8
20)21)22-11-14-5-4-6-15(10-14)25-3/h4-11H
In HeLa or U937 cells
A Phase II study of intravenous exatecan administered daily for 5 days
coli W3110 colonies resistant to 1 μg/mL CHIR-090 are not observed without prior chemical mutagenesis
Agomelatine enhances cell proliferation and neurogenesis in the ventral hippocampus (VH) of adult rats
PF-06463922 5109 HCl 20)21)22-11-14-5-4-6-15(10-14)25-3/h4-11HLorlatinib, also known as PF 06463922, is an orally available, ATP competitive inhibitor of the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK) and C ros oncogene 1 (Ros1), with potential antineoplastic activity. Upon administration, ALK ROS1 inhibitor PF 06463922 binds to and inhibits both ALK and ROS1 kinases. The kinase inhibition leads to disruption of ALK and ROS1 mediated signaling and eventually inhibits tumor cell growth in ALK and
US$ 229.03
US$ 669.82
US$ 855.23
US$ 56.36
US$ 20.00
US$ 123.69